Compare UGI & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UGI | TGTX |
|---|---|---|
| Founded | 1940 | 1993 |
| Country | United States | United States |
| Employees | 9400 | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.5B |
| IPO Year | N/A | 2008 |
| Metric | UGI | TGTX |
|---|---|---|
| Price | $36.38 | $53.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $44.00 | ★ $49.80 |
| AVG Volume (30 Days) | 1.3M | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.99% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | $8.88 | $49.08 |
| Revenue Next Year | $2.27 | $26.69 |
| P/E Ratio | ★ $14.04 | $449.67 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.62 | $25.37 |
| 52 Week High | $41.34 | $59.30 |
| Indicator | UGI | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.09 | 54.75 |
| Support Level | $35.66 | $51.15 |
| Resistance Level | $37.58 | $58.34 |
| Average True Range (ATR) | 0.68 | 2.44 |
| MACD | 0.12 | -0.80 |
| Stochastic Oscillator | 64.93 | 37.18 |
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.